Identification of Novel Putative Endogeneous Angiogenic Protein Inhibitors

The present invention identified over 70 novel putative endogenous angiogenesis inhibitors using methods of bioinformatics. Classification of these inhibitors is based on conserved domains of known anti-angiogenic fragments. Utilizing bioinformatics algorithms and searching the human protein database, novel inhibitors were identified. These newly identified proteins and protein segments constitute novel drug candidates for anti-angiogenesis therapeutics. Background Angiogenesis, the process of developing new blood vessels from the pre-existing vascular network, is controlled by various endogenous regulators. These regulatory elements include anti-angiogenic proteins that modulate the morphology and functional characteristics of the vascular system. Many regulators have been determined from extra cellular matrix proteins or from the circulating factors. Presently, the identification of novel angiogenic inhibitors is experimentally time consuming. Description (Set) Proposed Use (Set) The identified proteins and protein segments are novel drug candidates for anti-angiogenic therapies. They can be used in therapeutics applications to cancer, diabetic retinopathy, age-related macular degeneration, rheumatoid arthritis, obesity, would healing, inflammatory diseases, ischemic heart and peripheral vascular disease, and myocardial infarction.

Inventor(s): Popel, Aleksander S.

Type of Offer: Licensing



« More Medical Patents

---